Skip to content
TransBioline Logo TransBioline Logo TransBioline Logo
  • Home
  • Project
  • Consortium
    • Partners
    • Experts
  • News
    • Latest News
    • Newsletters
    • Publications
    • Outputs
    • Events
  • Project Legacy
    • Biosample Repository
    • TransBioLine Database
  • Login
Loading...
  • Meet the experts

    Since the beginning of TransBioLine, intense partners collaboration, scientific interactions among peers, and participants commitment have resulted in an Experts’ network in the development and qualification of safety biomarkers. In this section, you can find out more about the TransBioLine experts.

  • TransBioLine promises a decisive advance in biomarker discovery, development, validation, regulatory qualification and application, and bring about a fundamental change in the way drug safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice.

Meet the expert – Intro2024-07-29T12:10:14+00:00

Shashi Ramaiah

Sophia Samodelov

Guruprasad P. Aithal

Sara Paciga

Tanja S. Zabka

Jane Grove

Tom Lanz

Kseniya Khamina-Kotisc

Anthony Evans

imitransbioline IMI2_TransBioLine @imitransbioline ·
3 Feb

As we are reaching the Project end, we would like to thank all Partners for their dedicated work over the last 6 years!
38 publications are just a small pict of the project impact on #biomarkers
👉 http://transbioline.com
#IHICarryTheTorch #H2020 #EUHealthResearch @IHIEurope

Reply on Twitter 1886332983012995226 Retweet on Twitter 1886332983012995226 Like on Twitter 1886332983012995226 2 Twitter 1886332983012995226
Load More
ABOUT IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.

IMI Europa
info@transbioline.com
© Copyright    |   TransBioLine   |   Disclaimer: The TransBioLine website reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
Twitter
Page load link
This website uses cookies and third party services. Ok
Go to Top